Roadshow – Frankfurt

Bad Homburg, 24 February 2017

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: FY/2016 Highlights

HELIOS internationalization: Acquisition of Quirónsalud

All business segments contributed to solid organic growth

Continued double-digit earnings growth

Positive outlook for 2017

Ambitious new mid-term targets

Fresenius Group: 24th Consecutive Dividend Increase

Dividend growth aligned to EPS growth Pay-out ratio: 22%

¹ Proposal

Fresenius Group: FY/2016 Key Financials

Constant currency growth rates

2015 EBIT before special items

Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items

Fresenius Group: Profit and Loss Statement

€m	Q4/2016	Q4 YoY1 Δ	FY/2016	FY YoY1 Δ
Sales	7,738	6%	29,083	6%
EBIT2	1,235	11%	4,327	10%
Net interest	-149	-8%	-582	5%
Income taxes2	-305	-9%	-1,051	-8%
Net income2,3	439	7%	1,593	13%

¹ Constant currency growth rates

² 2015 before special items

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Fresenius Group: FY/2016 Key Financials

2015 EBIT before special items

Fresenius Kabi: Organic Sales Growth by Regions

Total sales	1,550	3%	6,007	5%
Asia-Pacific/Latin America/Africa	442	7%	1,702	10%
Latin America/Africa	155	8%	594	14%
Asia-Pacific	287	6%	1,108	8%
North America	542	-1%	2,170	3%
Europe	566	4%	2,135	3%
€m	Q4/2016	Organic Growth	FY/2016	Organic Growth

Fresenius Kabi: EBIT

€m	Q4/2016	Q4 YoY1 Δ	FY/2016	FY YoY1 Δ
Europe	100	8%	343	0%
Margin	17.7%	60 bps	16.1%	-50 bps
North America	168	-15%	837	5%
Margin	31.0%	-490 bps	38.6%	50 bps
Asia-Pacific/Latin America/Africa	103	21%	348	19%
Margin	23.3%	230 bps	20.4%	230 bps
Corporate and Corporate R&D	-63	-2%	-304	-16%
Total EBIT	308	-1%	1,224	5%
Margin	19.9%	-100 bps	20.4%	40 bps

¹ Constant currency growth rates

2015 before special items

Margin growth at actual rates

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Fresenius Kabi (1/2): Expected Organic Sales Growth 2017

North America

Mid-single-digit

Comps remain tough, following two exceptional years
Outlook assumes gradual further easing of IV drug shortages, more competition on some key molecules and continued price pressure
Vigorous launch activity in 2017: >10 product launches expected

Europe

Low to mid-single-digit

• Improving contract manufacturing business

Fresenius Kabi (2/2): Expected Organic Sales Growth 2017

Emerging Markets

Likely double-digit

China: new tender policy implementation expected to be mostly completed end of H1/2017; low to mid single digit price decline and continued double-digit volume growth projected
Asia-Pacific excl. China: ongoing recovery healthy growth expected
Latin America /Africa: Continued strong growth expected

Fresenius Helios

HELIOS Kliniken

German Hospital Structures Act considered neutral for 2017 HELIOS results
Continued favorable reimbursement environment; DRG inflator set at 2.50%
Niederberg contributed positively in 2016
FY/16 in line with outlook:
− Sales of €2,540 m (+16%, 6% org.)
− EBITDA2 of €461 m (+16%)
Successful financing: Cost of debt ~1.7%
Consolidation since February 1, 2017

1 Organic sales growth

2 Before special items; primarily relating to the transaction

€m	Q4/2016	Δ Q4 YoY	FY/2016	Δ FY YoY
Total sales	1,461	4%	5,843	5%
EBIT Established clinic portfolio	173	3%	679	6%
Margin	12.0%	10 bps	11.7%	20 bps
Acquisitions / Divestitures (consolidation / deconsolidation <1 yr) Margin	2 10.0%	-- --	3 6.0%	-- --
Total EBIT Margin	175 12.0%	4% 10 bps	682 11.7%	7% 20 bps

2015 before special items

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Fresenius Vamed

Strong Q4/16: 10% organic sales growth and 12% EBIT growth
€1,017 m order intake at all-time high, providing a solid basis for growth in FY/2017
Further expansion of geographic presence primarily in emerging and developing countries

€m	Q4/ 2016	Δ Q4 YoY	FY/ 2016	Δ FY YoY
Project business	269	11%	594	3%
Service business	151	4%	566	4%

Total sales	420	10%2	1,160	5%2
Total EBIT	38	12%	69	8%
Order intake1	343	-20%	1,017	13%

¹ Project business only

² Organic sales growth

Fresenius Group: Cash Flow

	Operating CF		Capex (net)		Free Cash Flow1
€m	Q4/2016	LTM Margin	Q4/2016	LTM Margin	Q4/2016	LTM Margin
	345	16.5%	-115	-5.4%	230	11.1%
	185	10.6%	-173	-5.9%	12	4.7%3
	5	2.3%	-5	-0.9%	0	1.4%
Corporate/Other	8	n.a.	-1	n.a.	7	n.a.
Excl. FMC	543	13.3%2	-294	-5.4%	249	7.9%2
	1,315	12.3%	-551	-5.5%	764	6.8%

¹ Before acquisitions and dividends

² Margin incl. FMC dividend

³ Understated: 5.4% excluding €43 million of capex commitments from acquisitions

Fresenius Group: 2017 Financial Outlook by Business Segment

otherwise	stated	20161 Base	2017e1
Sales growth (organic)	6,007	5% – 7%
	EBIT growth (cc)	1,171	5% – 7%
	Sales growth (organic)	2 5,843	3% – 5%
Sales (reported)	2 5,843	~€8.6 billion thereof Quirónsalud3 ~€2.5 billion
	EBIT	2 683	1,020 –1,070 thereof Quirónsalud3: EBIT of €300 to €320m (EBITDA €480 to €500m, amortization €80m, depreciation €100m)
	Sales growth (organic)	1,160	5% – 10%
	EBIT growth	69	5% – 10%

¹ All data according to IFRS; for a detailed reconciliation of US-GAAP to IFRS please see slides 49-50.

² Helios Kliniken Germany, excluding Quirónsalud

³ 11 months consolidated

€m except otherwise stated		20161 Base	2017e1
Sales growth (cc)		29,471	15% – 17%
	Net income2 growth (cc)	1,560	17% – 20%

1 All data according to IFRS; for a detailed reconciliation of US-GAAP to IFRS please see slides 49-50. 2 Net income attributable to shareholders of Fresenius SE & Co.KGaA

Development Legacy Business Market Opportunities

Organic growth
Development of I.V. generics and nutrition products
Leverage on market access
Filling the blanks: roll-out of existing product portfolio
Bolt-on acquisitions
Enter new geographic markets
Enteral Nutrition for outpatients (e.g. digital tool)
Extension of product portfolio via acquisitions: New market segments, (e.g. OTC, Biosimilars), new therapeutic areas

HELIOS Kliniken Quirónsalud

Integrated clusters
Expanded use of telemedicine
Digital innovations
Treating patients as consumers
Selective acquisitions in Germany
Quality and technology leadership
Cross-selling opportunities with ORPs
Greenfield projects
Further market consolidation

Incremental pre-tax synergies of ~€50m p.a.

Building European platform for international patients

Further international expansion

Marketing of Existing Value Chain	Strengthening and Extension of Value Chain	Expansion of Geographic Presence
Integrated project and • service business model	High-end services •	Further market • penetration in existing
- Life cycle models	• Total operational	target markets
- PPP models	management of health care facilities	• New international market entries

Fresenius Group: Ambitious Mid-Term Targets

¹ Mid-point of the 2017 sales guidance, adjusted for current exchange rates

² Mid-point of the 2017 net income guidance, adjusted for current exchange rates

³ Calculated on the basis of the mid-point of the 2020 target range

At current exchange rates; excluding strategic acquisitions; at current IFRS rules

Attachments

Fresenius Group: Profit and Loss Statement

			Growth Q4 YoY		Growth FY YoY
€m	Q4/2016	actual rates	constant rates	FY/2016	actual rates	constant rates
Sales	7,738	7%	6%	29,083	5%	6%
EBIT1	1,235	11%	11%	4,327	9%	10%
Net interest	-149	-9%	-8%	-582	5%	5%
Income taxes1	-305	-9%	-9%	-1.051	-7%	-8%
Net income2	439	6%	7%	1,593	12%	13%

1 2015 before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Financial Results by Business Segment

	Q4/2016	Δ Q4 YoY
Sales	US\$4,687 m	8%
EBIT	US\$786 m	19%
Sales	€1,550 m	2%
EBIT1	€308 m	-3%
Sales	€1,461 m	4%
EBIT	€175 m	4%
Sales	€420 m	9%
EBIT	€38 m	12%

1 2015 before special items

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Fresenius Group: Overview – Calculation of Noncontrolling Interest

€m	FY/2016	FY/2015
Earnings before tax and noncontrolling interest	3,745	3,262
Taxes	-1,051	-965
Noncontrolling interest, thereof	-1,101	-939
Fresenius Medical Care net income not attributable to Fresenius (Q1–4/16: ~69%)	-776	-641
Noncontrolling interest holders in Fresenius Medical Care (Q1–4/16: US\$306 m according to Fresenius Medical Care's Financial Statements)	-276	-256
Noncontrolling interest holders in Fresenius Kabi (-€36 m), Fresenius Helios (-€2 m), Fresenius Vamed (-€1 m) and due to Fresenius Vamed's 23% external ownership (-€10 m)	-49	-42
Net income attributable to Fresenius SE & Co. KGaA	1,593	1,358

€m	FY/2016	LTM Margin	FY/2015	LTM Margin	Δ YoY
Operating Cash Flow	3,574	12.3%	3,327	12.0%	7%
Capex (net)	-1,603	-5.5%	-1,462	-5.2%	-10%
Free Cash Flow (before acquisitions and dividends)	1,971	6.8%	1,865	6.8%	6%
Acquisitions (net)	-485		-32		--
Dividends	-738		-639		-15%
Free Cash Flow (after acquisitions and dividends)	748	2.6%	1,194	4.3%	-37%

		Operating CF Capex (net)			Free Cash Flow1
€m	FY/2016	LTM Margin	FY/2016	LTM Margin	FY/2016	LTM Margin
	991	16.5%	-323	-5.4%	668	11.1%
	622	10.6%	-349	-5.9%	273	4.7%3
	27	2.3%	-11	-0.9%	16	1.4%
Corporate/Other	1	n.a.	-6	n.a.	-5	n.a.
Excl. FMC	1,717	13.3%2	-689	-5.4%	1,028	7.9%2
	3,574	12.3%	-1.603	-5.5%	1,971	6.8%

¹ Before acquisitions and dividends

² Margin incl. FMC dividend

³ Understated: 5.4% excluding €43 million of capex commitments from acquisitions

Fresenius Group: Leverage Ratio*

*At annual average FX rates for both EBITDA and net debt

¹ Pro forma acquisitions; before special items

² Adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)

³ Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items

⁴ Before special items

⁵ Pro forma acquisitions

⁶ Pro forma Quirónsalud: 3.1

⁷ Calculated at expected annual average exchange rates, for both net debt and EBITDA; without large unannounced acquisitions

Fresenius Group: Consistent Cash Generation And Proven Track Record of Deleveraging

CFFO margin FCF margin (before acquisitions & dividends)

Capex in % of sales

1 Net debt at year-end exchange rate; EBITDA at LTM average exchange rates 2 Pro forma Quirónsalud: 3.2

Net Debt / EBITDA1

Fresenius Group: Solid Balance Sheet Structure

Fresenius Group Debt Maturity Profile¹ December 31, 2016 Pro Forma2

¹ Based on utilization of major financing instruments

² Pro Forma the acquisition of Quironsalud: €2.6bn Senior Notes, €1.2bn Incremental facilities, € 1.0bn Schuldschein loans and €500 million Synthetic Convertible bonds

Fresenius Group: Components of the Debt Financing for the Acquisition of Quirónsalud

Maturity profile

Average maturity 7.0 years.

Financing mix

Fresenius Kabi: Organic Sales Growth by Product Segment

Total sales	1,550	3%	6,007	5%
Transfusion Technology
Medical Devices/	262	-9%	1,039	1%
Clinical Nutrition	403	7%	1,576	7%
Infusion Therapy	225	7%	861	6%
IV Drugs	660	5%	2,531	5%
€m	Q4/2016	Organic Growth	FY/2016	Organic Growth

Fresenius Kabi: Profit and Loss Statement

€m	2016	2015	Remarks 2016
Sales	6,007	5,950	5% organic growth
EBITDA margin %	1,479 24.6	1,446 24.3
EBIT margin %	1,224 20.4	1,189 20.0
Net interest	-149	-184
Earnings before taxes and noncontrolling interest	1,075	1,005
Income taxes Tax rate %	-323 30.0	-306 30.4
Noncontrolling interest	-36	-30
Net income1	716	669

2015 before special items

¹ Attributable to shareholders of Fresenius Kabi AG

Fresenius Kabi: Cash Flow Statement

€m	2016	2015	Remarks 2016
Net income1 (incl. noncontrolling interest)	752	610
Depreciation / amortization	255	257
Change in working capital	-16	46
Cash flow from operations Margin %	991 16.5	913 15.3
CAPEX, net	-323	-324	66% discretionary (2015: 67%) 34% non-discretionary (2015: 33%)
Cash flow before acquisitions and dividends	668	589
Acquisitions, net	-114	-16
Free cash flow (before dividends)	554	573

¹ After special items

Fresenius Kabi: Balance Sheet

€m	2016	2015	Remarks 2016
Accounts receivable	769	747	DSO 2016: 47 days (2015: 46)
Inventories	1,354	1,202	SOI 2016: 152 days (2015: 135)
Fixed assets	7,637	7,277	Goodwill (Dec 31, 2016): €5.2 bn
Other assets	1,365	1,169
Total assets	11,125	10,395
Debt	5,155	5,234
Other liabilities	2,256	2,053
Equity (incl. noncontrolling int.)	3,714	3,108
Total liabilities and shareholders' equity	11,125	10,395

Fresenius Helios: Strong Sales Growth

€m	Q4/2016	Δ Q4 YoY	FY/2016	Δ FY YoY
Established clinic portfolio	1,441	2%	5,793	4%
Acquisitions (consolidation <1 yr)	20	n.a.	50	n.a.
Total Sales	1,461	4%	5,843	5%

For a detailed overview of special items please see the reconciliation tables on slides 49–50.

Fresenius Helios: Performance Indicators

	FY/2016	FY/2015	Change
No. of hospitals Acute care clinics - Post-acute care clinics	112 88 24	111 87 24	1% 1% 0%
No. of beds - Acute care clinics - Post-acute care clinics	34,706 29,618 5,088	34,076 28,914 5,162	2% 2% -1%
Admissions - Acute care (inpatient)	1,229,125	1,193,423	3%
Occupancy - Post-acute care	82%	82%
Average length of stay (days) Acute care1 - - Post-acute care	6.4 26.1	6.4 26.4
Bad debt of sales	0.3%	0.2%

1 German average (2015): 7.3

Fresenius Helios: Profit & Loss Statement

€m	2016	2015	Remarks 2016
Sales	5,843	5,578	4% organic sales growth
EBITDA Margin % Depreciation / amortization	877 15.0 -195	831 14.9 -191
EBIT Margin %	682 11.7	640 11.5
Net interest	-37	-48
Earnings before taxes and noncontrolling interest	645	592
Income taxes Tax rate %	-100 15.5	-108 18.2
Noncontrolling interest	-2	-1
Net income1	543	483

Before special items

¹ Attributable to shareholders of HELIOS Kliniken GmbH

Fresenius Helios: Cash Flow

€m	2016	2015
Net income1 (incl. noncontrolling interest)	545	508
Depreciation / amortization	195	191
Change in working capital	-118	-80
Cash flow from operations Margin %	622 10.6	618 11.1
CAPEX, net	-349	-271
Cash flow before acquisitions and dividends	273	347
Acquisitions, net	-48	47
Free cash flow (before dividends)	225	394

¹ After special items

Fresenius Helios: Balance Sheet

€m	2016	2015	Remarks 2016
Accounts receivable	749	653	DSO 2016: 47 days (2015: 43)
Property, plant and equipment (net)	2,629	2,538
Goodwill	4,544	4,443
Other assets	779	796
Total assets	8,701	8,430
Debt	1,406	1,282	Incl. debt from 2005 HELIOS acquisition (€600 m)
Other liabilities	1,440	1,514
Equity (incl. noncontrolling interest)	5,855	5,634
Total liabilities and shareholders' equity	8,701	8,430

Fresenius Vamed: Sales and EBIT in Line with Expectations

€m	Q4/2016	Growth Q4 YoY	FY/2016	Growth FY YoY
Project business	269	11%	594	3%
Service business	151	4%	566	4%
Total sales	420	9%	1,160	4%
Total EBIT Margin	38 9.0%	12% 20 bps	69 5.9%	8% 20 bps
Order intake1	343	-20%	1,017	13%
Order backlog1			1,961	19%

¹ Project business only

Fresenius Vamed: Profit & Loss Statement

€m	2016	2015	Remarks 2016
Sales	1,160	1,118	5% organic growth
EBITDA	80	75
Margin %	6.9	6.7
EBIT	69	64
Margin %	5.9	5.7
Net interest	-2	-3
Earnings before taxes and noncontrolling interest	67	61
Income taxes	-21	-16
Tax rate %	31.0	26.2
Noncontrolling interest	-1	-1
Net income1	45	44
ROE (before taxes) %	19.6	19.4

¹ Attributable to shareholders of Vamed AG

Fresenius Vamed: Cash Flow

€m	2016	2015
Net income (incl. noncontrolling interest)	46	45
Depreciation / amortization	11	11
Change in working capital	-30	-3
Cash flow from operations Margin %	27 2.3	53 4.7
CAPEX, net	-11	-11
Cash flow (before acquisitions and dividends)	16	42
Acquisitions, net	0	-4
Free cash flow (before dividends)	16	38

Fresenius Vamed: Balance Sheet

€m	2016	2015	Remarks 2016
Accounts receivable	209	198	DSO 2016: 66 days (2015: 65)
Property, plant and equipment	72	71
Intangible assets	103	104
Other assets	724	615
Total assets	1,108	988
Debt	176	161
Other liabilities	591	513
Equity (incl. noncontrolling interest)	341	314
Total liabilities and shareholders' equity	1,108	988

€m except otherwise	stated	2016 according to U.S. GAAP	Δ	2016 according to IFRS
Sales EBIT		6,007	--	6,007
	1,224	-53 1	1,171
	Sales	5,843 2	--	5,843 2
	EBIT	682 2	1	683 2
	Sales	1,160	--	1,160
	EBIT	69	--	69

¹ Under IFRS, research and development expenses include non-recurring valuation losses on capitalized development expenses. These relate to in-process R&D of product approval projects which were bought with the acquisition of Fresenius Kabi USA, Inc. Under US-GAAP these expenses were already recognized at the time of acquisition. Moreover differences stem from the timing of accruals.

² Helios Kliniken Germany, excluding Quirónsalud

€m		2016 according to U.S. GAAP	Δ	2016 according to IFRS
	Sales	29,083	388 1	29,471
	Net income2	1,593	33 3	1,560

¹ Under U.S. GAAP, certain value adjustments for receivables at Fresenius Medical Care North America were directly deducted from sales.

² Net income attributable to shareholders of Fresenius SE & Co.KGaA

³ Under IFRS, research and development expenses include non-recurring valuation losses on capitalized development expenses. These relate to in-process R&D of product approval projects which were bought with the acquisition of Fresenius Kabi USA, Inc. Under US-GAAP these expenses were already recognized at the time of acquisition. Moreover differences stem from the timing of accruals.

Fresenius Group: Key Figures According to IFRS

€m	FY/2016 U.S. GAAP	FY/2016 IFRS
Sales	29,083	29,471
EBIT	4,327	4,302
Net interest	-582	-582
Net income	1,5931	1,5601
Operating cash flow	3,574	3,585
Balance sheet total	46,447	46,697

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Reconciliation according to U.S. GAAP Q4 2016/ Q4 2015

The Group's U.S. GAAP financial results as of December 31, 2016 do not include special items, whereas the U.S. GAAP financial results as of December 31, 2015 include special items. Net income attributable to shareholders of Fresenius SE & Co.KGaA was adjusted for these special items. The table below shows the special items and the reconciliation from net income (before special items) to earnings according to U.S. GAAP.

Net income attributable to shareholders of Fresenius SE & Co. KGaA	414	-55	0	0	359
Noncontrolling interest	-278				-278
Net income	692	-55	0	0	637
Income taxes	-280				-280
Net income before taxes	972	-55	0	0	917
Interest result	-137				-137
EBIT	1,109	-55	0	0	1,054
Sales	7,257				7,257
€m	Q4/2015 before special items	efficiency program KABI	integration costs for acquired Rhön hospitals	disposal gains from two HELIOS hospitals	Q4/2015 according to U.S. GAAP (incl. special items)

The special items are reported in the Group Corporate/Other segment.

Reconciliation according to U.S. GAAP FY 2016/FY 2015

Net income attributable to shareholders of Fresenius SE & Co. KGaA	1,423	-89	-10	34	1,358
Noncontrolling interest	-939				-939
Net income	2,362	-89	-10	34	2,297
Income taxes	-983	16	2		-965
Net income before taxes	3,345	-105	-12	34	3,262
Interest result	-613				-613
EBIT	3,958	-105	-12	34	3,875
Sales	27,626				27,626
€m	FY/2015 before special items	efficiency program KABI	integration costs for acquired Rhön hospitals	disposal gains from two HELIOS hospitals	FY/2015 according to U.S. GAAP (incl. special items)

The special items are reported in the Group Corporate/Other segment.

Financial Calendar / Contact

Financial Calendar 2017

03.05.2017	Report on 1st quarter 2017
12.05.2017	Annual General Meeting, Frankfurt/Main
01.08.2017	Report on 2nd quarter 2017
02.11.2017	Report on 3rd quarter 2017

Please note that these dates could be subject to change.

Contact

Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: [email protected] For further information and current news: www.fresenius.com

AI Terminal

Fresenius SE & Co. KGaA

166_ip_2017-02-24_88f6c7a6-58e2-4831-90f4-5f1ed66c0723.pdf

Roadshow – Frankfurt

Fresenius Group: FY/2016 Highlights

Fresenius Group: 24th Consecutive Dividend Increase

Fresenius Group: FY/2016 Key Financials

Fresenius Group: Profit and Loss Statement

Fresenius Group: FY/2016 Key Financials

Fresenius Kabi: Organic Sales Growth by Regions

Fresenius Kabi: EBIT

Fresenius Kabi (1/2): Expected Organic Sales Growth 2017

North America

Mid-single-digit

Europe

Low to mid-single-digit

Fresenius Kabi (2/2): Expected Organic Sales Growth 2017

Emerging Markets

Likely double-digit

Fresenius Helios

HELIOS Kliniken

Fresenius Vamed

Fresenius Group: Cash Flow

Fresenius Group: 2017 Financial Outlook by Business Segment

Development Legacy Business Market Opportunities

HELIOS Kliniken Quirónsalud

Fresenius Group: Ambitious Mid-Term Targets

Attachments

Fresenius Group: Profit and Loss Statement

Financial Results by Business Segment

Fresenius Group: Overview – Calculation of Noncontrolling Interest

Fresenius Group: Leverage Ratio*

Fresenius Group: Consistent Cash Generation And Proven Track Record of Deleveraging

CFFO margin FCF margin (before acquisitions & dividends)

Capex in % of sales

Net Debt / EBITDA1

Fresenius Group: Solid Balance Sheet Structure

Fresenius Group Debt Maturity Profile1 December 31, 2016 Pro Forma2

Fresenius Group: Components of the Debt Financing for the Acquisition of Quirónsalud

Maturity profile

Fresenius Kabi: Organic Sales Growth by Product Segment

Fresenius Kabi: Profit and Loss Statement

Fresenius Kabi: Cash Flow Statement

Fresenius Kabi: Balance Sheet

Fresenius Helios: Strong Sales Growth

Fresenius Helios: Performance Indicators

Fresenius Helios: Profit & Loss Statement

Fresenius Helios: Cash Flow

Fresenius Helios: Balance Sheet

Fresenius Vamed: Sales and EBIT in Line with Expectations

Fresenius Vamed: Profit & Loss Statement

Fresenius Vamed: Cash Flow

Fresenius Vamed: Balance Sheet

Fresenius Group: Key Figures According to IFRS

Reconciliation according to U.S. GAAP Q4 2016/ Q4 2015

Reconciliation according to U.S. GAAP FY 2016/FY 2015

Financial Calendar / Contact

Financial Calendar 2017

Contact

More from Fresenius SE & Co. KGaA

Talk to a Data Expert

Fresenius Group Debt Maturity Profile¹ December 31, 2016 Pro Forma2